文献速递流行病学与生物统计真实世界研究与卫生经济

已发表的注册数据库药物流行病学关联与无假设全药物分析结果一致性有限

Published registry-based pharmacoepidemiologic associations show limited concordance with agnostic medication-wide analyses.
PubMed 文献 · J Clin Epidemiol · 2023-05-22

该研究系统检索了瑞典处方药注册库中报告药物与任何癌症、乳腺癌、结肠/结直肠癌或前列腺癌关联的已发表文献,并与同一注册库此前完成的无假设全药物分析进行比较。大多数已发表研究(25/32)针对既往报道的关联,421/913(46%)的关联具有统计学显著结果。已发表研究报道的效应量和绝对效应量均小于无假设分析,且无假设分析报告统计学显著保护性关联的可能性更低(McNemar比值比0.13,P=0.0022)。

要点

  • 已发表注册库药物流行病学研究多针对既往报道的关联,且多为阴性结果。
  • 已发表研究报道的效应量和绝对效应量小于同一注册库的无假设全药物分析。
  • 无假设分析报告统计学显著保护性关联的可能性低于已发表配对关联(McNemar比值比0.13,P=0.0022)。

核心结论

  • 使用国家注册库的已发表药物流行病学研究大多针对既往提出的关联,结果多为阴性,且与同一注册库中相应的无假设分析仅显示适度一致性。

研究设计与样本

  • 系统检索瑞典处方药注册库中报告药物与任何癌症、乳腺癌、结肠/结直肠癌或前列腺癌关联的已发表研究,并与同一注册库此前完成的无假设全药物分析进行比较。

主要发现

  • 大多数已发表研究(25/32)调查的是既往报道的关联;421/913(46%)的关联具有统计学显著结果。
  • 162个独特药物-癌症关联中的134个可与无假设研究中的70个关联配对(对应药物类别和癌症类型)。
  • 已发表研究报道的效应量和绝对效应量均小于无假设研究,且通常使用更多调整。
  • 无假设分析报告统计学显著保护性关联(基于多重校正阈值)的可能性低于已发表研究中的配对关联(McNemar比值比0.13,P=0.0022)。
  • 在162个已发表关联中,36个(22%)在P<0.05时显示风险增加信号,25个(15%)显示保护性信号;而无假设关联中,237个(11%)在多重校正阈值下显示风险增加信号,108个(5%)显示保护性信号。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess how the results of published national registry-based pharmacoepidemiology studies (where select associations are of interest) compare with an agnostic medication-wide approach (where all possible drug associations are tested). STUDY DESIGN AND SETTING: We systematically searched for publications that reported drug associations with any, breast, colon/colorectal, or prostate cancer in the Swedish Prescribed Drug Registry. Results were compared against a previously performed agnostic medication-wide study on the same registry. PROTOCOL: https://osf.io/kqj8n. RESULTS: Most published studies (25/32) investigated previously reported associations. 421/913 (46%) associations had statistically significant results. 134 of the 162 unique drug-cancer associations could be paired with 70 associations in the agnostic study (corresponding drug categories and cancer types). Published studies reported smaller effect sizes and absolute effect sizes than the agnostic study, and generally used more adjustments. Agnostic analyses were less likely to report statistically significant protective associations (based on a multiplicity-corrected threshold) than their paired associations in published studies (McNemar odds ratio 0.13, P = 0.0022). Among 162 published associations, 36 (22%) showed increased risk signal and 25 (15%) protective signal at P < 0.05, while for agnostic associations, 237 (11%) showed increased risk signal and 108 (5%) protective signal at a multiplicity-corrected threshold. Associations belonging to drug categories targeted by individual published studies vs. nontargeted had smaller average effect sizes; smaller P values; and more frequent risk signals. CONCLUSION: Published pharmacoepidemiology studies using a national registry addressed mostly previously proposed associations, were mostly "negative", and showed only modest concordance with their respective agnostic analyses in the same registry.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Axfors C, Patel CJ, Ioannidis JPA, et al. Published registry-based pharmacoepidemiologic associations show limited concordance with agnostic medication-wide analyses. J Clin Epidemiol. 2023. PMID: 37224981. doi:10.1016/j.jclinepi.2023.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。